Stabilizing Off-pathway Oligomers by Polyphenol Nanoassemblies for IAPP Aggregation Inhibition

被引:0
作者
Praveen Nedumpully-Govindan
Aleksandr Kakinen
Emily H. Pilkington
Thomas P. Davis
Pu Chun Ke
Feng Ding
机构
[1] Clemson University,Department of Physics and Astronomy
[2] ARC Centre of Excellence in Convergent Bio-Nano Science and Technology,Department of Chemistry
[3] Monash Institute of Pharmaceutical Sciences,undefined
[4] Monash University,undefined
[5] University of Warwick,undefined
来源
Scientific Reports | / 6卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Experimental studies have shown that many naturally occurring polyphenols have inhibitory effect on the aggregation of several proteins. Here, we use discrete molecular dynamics (DMD) simulations and high-throughput dynamic light scattering (DLS) experiments to study the anti-aggregation effects of two polyphenols, curcumin and resveratrol, on the aggregation of islet amyloid polypeptide (IAPP or amylin). Our DMD simulations suggest that the aggregation inhibition is caused by stabilization of small molecular weight IAPP off-pathway oligomers by the polyphenols. Our analysis indicates that IAPP-polyphenol hydrogen bonds and π-π stacking combined with hydrophobic interactions are responsible for the stabilization of oligomers. The presence of small oligomers is confirmed with DLS measurements in which nanometer-sized oligomers are found to be stable for up to 7.5 hours, the time frame within which IAPP aggregates in the absence of polyphenols. Our study offers a general anti-aggregation mechanism for polyphenols and further provides a computational framework for the future design of anti-amyloid aggregation therapeutics.
引用
收藏
相关论文
共 167 条
[1]  
Glabe CG(2006)Common mechanisms of amyloid oligomer pathogenesis in degenerative disease Neurobiol. Aging 27 570-575
[2]  
Kayed R(1999)Conformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation J. Mol. Biol. 287 781-796
[3]  
Macdonald IA(1997) 1 Diabet. Med. J. Br. Diabet. Assoc. 14 S24-28
[4]  
Young DA(1990)Amylin and the gastrointestinal tract Am. J. Physiol.-Endocrinol. Metab. 259 E457-909
[5]  
Deems RO(2003)Effects of amylin on glucose metabolism and glycogenolysis Nature 426 905-321
[6]  
Deacon RW(2000) and Nat. Struct. Biol 7 312-3644
[7]  
McIntosh RH(2005)Therapeutic approaches to protein-misfolding diseases Proc. Natl. Acad. Sci. USA 102 3639-2718
[8]  
Foley JE(2010)Rational design of potent human transthyretin amyloid disease inhibitors J. Med. Chem. 53 2709-8855
[9]  
Cohen FE(2015)Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation Sci. Rep 5 8240-101
[10]  
Kelly JW(2001)Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods Proc. Natl. Acad. Sci. USA 98 8850-199